MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Diabetes (Glucometers, Glucose Monitoring, Continuous Glucose Monitoring [CGM] Companies)
Eyesense AG
Parents
Architects: Diabetes (Glucometers, Glucose Monitoring, Continuous Glucose Monitoring [CGM] Companies)
Architects: Diabetes, Dialysis, Renal & Kidney Disease Companies (Health IT, Devices & Technology)
Industry: Switzerland
Children
2011: EyeSense Attracts QIAGEN as Strategic Investor (2011)
Achim Muller, CEO and co-founder of EyeSense AG
Based on a highly innovative product concept: an ophthalmic diagnostics system which can measure glucose levels without sampling blood each time, solely via a non-invasive sensor technology.
Basel, Switzerland
EyeSense has the goal of making Blood Glucose Monitoring (BGM) easier and painless
Founded 2008
Investors include BioMedinvest, Life Sciences Partners, Novartis Venture Fund, Private Life Bio Med, Alstertor Private Life, Bayern Kapital
It is planned to launch the new BGM device in 2013.
Spin-off of Novartis AG, Basle and CIBA Vision, Atlanta, USA
Jumps
CIBA Vision
Novartis AG (NYSE: NVS)*
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA)